These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 852367)

  • 1. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.
    Jellinek T
    Dis Nerv Syst; 1977 May; 38(5):353-5. PubMed ID: 852367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biperiden (Akineton): effective prophylactic and therapeutic anti-parkinsonian agent.
    Kline NS; Mason BT; Winick L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):838-43. PubMed ID: 4155670
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
    Kammerer T; Schweitzer-Bucher E; Jamet P; Royer M
    Ann Med Psychol (Paris); 1972 May; 1(5):688-96. PubMed ID: 5081112
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical-neuroleptic investigation of N-((1-ethyl-pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutly ill schizophrenics].
    Haase HJ; Floru L; Ulrich F
    Int Pharmacopsychiatry; 1974; 9(2):77-94. PubMed ID: 4603413
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
    Klett CJ; Caffey E
    Arch Gen Psychiatry; 1972 Apr; 26(4):374-9. PubMed ID: 4552131
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dependence on anticholinergics among schizophrenics. Iatrogenic disease or self-medication?].
    Chamorro García L
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1991; 19(6):298-303. PubMed ID: 1687233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effects of antiparkinson drug withdrawal.
    Jellinek T; Gardos G; Cole JO
    Am J Psychiatry; 1981 Dec; 138(12):1567-71. PubMed ID: 6118066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
    Wada Y; Yamaguchi N
    Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
    Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
    Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical trial of delayed-action Akinophyl (Akineton)].
    Delteil P; Decreton C
    Ann Med Psychol (Paris); 1972 May; 1(5):696-709. PubMed ID: 5081113
    [No Abstract]   [Full Text] [Related]  

  • 11. No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
    Silver H; Geraisy N
    Biol Psychiatry; 1995 Sep; 38(6):413-5. PubMed ID: 8547463
    [No Abstract]   [Full Text] [Related]  

  • 12. A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.
    McEvoy JP
    J Clin Psychiatry; 1987 Sep; 48 Suppl():20-3. PubMed ID: 2887553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of the neuroleptic syndrome by biperiden hydrochloride under its delayed-action form. A 9-month study on 55 hospitalized patients].
    Verdeau-Pailles J
    Encephale; 1976; 2(4):341-7. PubMed ID: 1001242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats.
    Myhrer T; Enger S; Aas P
    Pharmacol Biochem Behav; 2008 Jun; 89(4):633-8. PubMed ID: 18384867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothermia caused by antipsychotic drugs in a schizophrenic patient.
    Noto T; Hashimoto H; Sugae S; Okamoto K; Nakao J; Kamimura H; Nakajima T
    J Clin Psychiatry; 1987 Feb; 48(2):77-8. PubMed ID: 3804993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tactile hallucinations induced by trihexyphenidyl in a patient with Parkinson's disease].
    Funakawa I; Jinnai K
    Rinsho Shinkeigaku; 2005 Feb; 45(2):125-7. PubMed ID: 15782612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive use of anticholinergic drugs in a sub-sample of Italian schizophrenics.
    Schifano F; di Costanzo E
    Int J Clin Pharmacol Ther Toxicol; 1991 May; 29(5):184-6. PubMed ID: 2071270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia with risperidone and anticholinergics.
    Suzuki E; Obata M; Yoshida Y; Miyaoka H
    Am J Psychiatry; 2002 Nov; 159(11):1948. PubMed ID: 12411240
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of negative schizophrenic symptoms with trihexyphenidyl.
    Tandon R; Greden JF; Silk KR
    J Clin Psychopharmacol; 1988 Jun; 8(3):212-5. PubMed ID: 3379147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.